Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026

Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or COVID vaccine injuryParticipants to include people ...
Seeking Alpha

ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID

Approximately one in five American adults who had COVID-19 still experience symptoms of long COVID, a serious illness that can result in chronic conditions and disability 1.2 Long COVID remains a ...
Seeking Alpha

Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population

Recruitment completed and all doses administered for VYD2311 ongoing Phase 1/2 clinical trial (40 subjects) evaluating 3 routes of administration Phase 1/2 clinical data for VYD2311 to date are ...

Invivyd (IVVD) reports strong Q4 growth, advances COVID antibody to phase 3

Invivyd, Inc. (NASDAQ:IVVD) is one of the best penny stocks to buy in 2026. On January 8, Invivyd, Inc. (NASDAQ:IVVD) ...
EurekAlert!

Inhaled COVID vaccine begins recruitment for phase-2 human trials

Researchers at McMaster University have started a phase-2 clinical trial on a next-generation, inhaled COVID-19 vaccine. The AeroVax study, supported by $8M in funding from the Canadian Institutes of ...